98%
921
2 minutes
20
Background: Primary percutaneous coronary intervention (pPCI) with drug-eluting stents (DES) has emerged as the standard of care, but stent-related events have persisted. Drug-coated balloon (DCB)-only angioplasty is an emerging technology, although it is not fully evaluated compared with DES in the context of pPCI.
Objectives: The aim of this study was to investigate the safety of DCB-only angioplasty compared with second-generation DES in pPCI.
Methods: All-cause mortality and net adverse cardiac events (cardiovascular mortality, acute coronary syndrome, ischemic stroke or transient ischemic attack, major bleeding, and unplanned target lesion revascularization [TLR]) were compared among all patients treated with DCBs only or with second-generation DES only for first presentation of ST-segment elevation myocardial infarction (STEMI) due to de novo disease between January 1, 2016, and November 15, 2019. Patients treated with both DCBs and DES were excluded. Data were analyzed using Cox regression models, Kaplan-Meier estimator plots and propensity score matching.
Results: Among 1,139 patients with STEMI due to de novo disease, 452 were treated with DCBs and 687 with DES. After a median follow-up period of >3 years, all-cause mortality was 49 of 452 and 62 of 687 in the DCB and DES groups, respectively (P = 0.18). On multivariable Cox regression analysis, there was no difference in mortality between DCBs and DES in the full and propensity score-matched cohorts. Age, frailty risk, history of heart failure, and family history of ischemic heart disease remained significant independent predictors of mortality. There was no difference in any of the secondary endpoints, including unplanned TLR.
Conclusions: DCB-only angioplasty appears safe compared with DES for STEMI in terms of all-cause mortality and all net adverse cardiac events, including unplanned TLR. DCB may be an efficacious and safe alternative to DES in selected patient groups. (Drug Coated Balloon Only vs Drug Eluting Stent Angioplasty; NCT04482972).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcin.2023.01.380 | DOI Listing |
Clin Cardiol
August 2025
Clinical Trials Unit, Centre Hospitalier la Rochelle, la Rochelle, France.
Introduction: Drug-eluting stent (DES) angioplasty is the gold standard treatment for coronary lesions. Drug-coated balloon (DCB) is an option for in-stent restenosis, and has also shown promise for small-calibre coronary artery disease. We evaluated the 3-year effectiveness of a decision algorithm for percutaneous coronary intervention (PCI) that favoured a stent-less strategy (SLS) in primary angioplasty.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
The First Affiliated Hospital of Henan Polytechnic University, Jiaozuo, Henan, China.
Background: Drug-coated balloon (DCB) has become a common treatment, but restenosis may still occur after DCB. The association of the triglyceride-glucose (TyG) index with coronary atherosclerotic heart disease prognosis has been demonstrated. However, the relationship between the TyG index and restenosis after DCB-only remains unknown.
View Article and Find Full Text PDFMedicine (Baltimore)
July 2025
Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
To evaluate the efficacy of drug-coated balloon (DCBs) therapy in de novo lesions compared with in-stent restenosis (ISR) in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). 149 patients with NSTE-ACS who underwent DCB-only strategy between March 2019 and March 2022 were retrospectively analyzed.Among those, 64 individuals underwent optical coherence tomography (OCT) prior to DCB dilatation.
View Article and Find Full Text PDFSci Rep
July 2025
Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, 310016, Zhejiang Province, People's Republic of China.
Drug-Coated Balloons (DCB) have been widely used in interventional treatment for coronary artery de novo lesions. However, DCB treatment still have a certain proportion of target vessel restenosis (TLR) and adverse follow-up events. Quantitative flow ratio (QFR) loss are important indicators for evaluating long-term vascular functional changes.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
August 2025
Department of Cardiology, Rakuwakai Otowa Hospital, Kyoto, Japan.
Background: The current study aimed to investigate whether scaffolds or repeat drug-coated balloons (DCBs) were more effective in preventing recurrent restenosis after repeat endovascular therapy (EVT) for early (within 12 months) and late (after 12 months) DCB restenosis.
Methods: This study retrospectively analyzed 234 limbs from 213 consecutive patients who underwent repeat EVT using scaffold (n = 52) or DCB only (n = 182) for primary DCB restenosis in femoropopliteal lesions at eight cardiovascular centers across Japan. Repeat EVT for early and late DCB restenosis was performed in 123 and 111 limbs, respectively.